538 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
SNY Sanofi $43.75 $109.14B N/A
Article Searches
Protalix Finalizes Accelerated Approval Pathway for PRX-102 http://www.zacks.com/stock/news/627355/protalix-finalizes-accelerated-approval-pathway-for-prx-102?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-627355 Nov 19, 2019 - Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
Top Stock Reports for Chevron, HSBC & Sanofi http://www.zacks.com/research-daily/621516/top-stock-reports-for-chevron-hsbc-sanofi?cid=CS-ZC-FT-research_daily-621516 Nov 15, 2019 - Top Stock Reports for Chevron, HSBC & Sanofi
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion http://www.zacks.com/stock/news/621335/amarin-amrn-gets-fda-panel-nod-for-vascepa-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-621335 Nov 15, 2019 - Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study http://www.zacks.com/stock/news/619720/glaxos-nucala-meets-goal-in-rare-inflammatory-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-619720 Nov 14, 2019 - GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products http://www.zacks.com/stock/news/610160/pharma-stock-roundup-agn-nvo-q3-earnings-fda-nod-to-sny-nvs-products?cid=CS-ZC-FT-analyst_blog|stock_roundup-610160 Nov 08, 2019 - Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales http://www.zacks.com/stock/news/608654/emergent-ebs-beat-earnings-in-q3-vaccines-drive-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-608654 Nov 07, 2019 - Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength http://www.zacks.com/stock/news/604780/regenerons-regn-q3-earnings-beat-on-dupixent-strength?cid=CS-ZC-FT-analyst_blog|earnings_article-604780 Nov 05, 2019 - Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates http://www.zacks.com/stock/news/598340/pharma-stock-roundup-mrk-pfe-gsk-bmy-q3-earnings-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-598340 Nov 01, 2019 - Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates http://www.zacks.com/stock/news/598292/alnylams-alny-q3-earnings-and-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-598292 Nov 01, 2019 - Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Sanofi (SNY) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/01/sanofi-sny-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Nov 01, 2019 - SNY earnings call for the period ending September 30, 2019.

Pages: 1234567891011...54

<<<Page 6>